SequelSEC

Neurogene Inc. NGNE

Pharmaceutical Preparations · CIK 0001404644 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$103.33M
Fiscal year ended 2025-12-31
Free cash flow
-$78.36M
Fiscal year ended 2025-12-31

Neurogene Inc. (NGNE) reported revenue of $0 and net income of -$90.35M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Neurogene Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Neurogene Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-31
Revenue$0$925.00K$0$25.00M
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$103.33M-$82.60M-$55.58M-$32.62M
Net income-$90.35M-$75.14M-$36.32M-$31.58M
Research & development$75.01M$60.92M$44.39M$41.79M
Weighted-average diluted sharesshares 21.33Mshares 17.57MUnavailableUnavailable
Pretax income-$90.35M-$75.14M-$36.32M-$31.58M
Income tax expense$0$0UnavailableUnavailable
Diluted EPS$-4.24$-4.28UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$28.32M$22.61M$11.19M$15.84M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Neurogene Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-31
Cash & equivalents$103.84M$136.59M$148.21M$76.93M
Total assets$288.60M$335.73M$222.57M$77.62M
Current assets$271.77M$315.92M$200.35M$77.16M
Total liabilities$23.72M$25.36M$36.55M$4.95M
Current liabilities$16.41M$15.16M$22.97M$4.63M
Total equity incl. NCI$264.89M$310.38M$186.02M$72.67M
Temporary (mezzanine) equityUnavailableUnavailable$0Unavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.95M$1.34M$2.60MUnavailable

Cash flow

Neurogene Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-31
Operating cash flow-$77.17M-$70.60M-$51.42M-$31.58M
Capital expenditures$1.18M$808.00K$321.00K$49.00K
Investing cash flow$14.00M-$125.26M$25.64M$55.95M
Financing cash flow$30.43M$184.07M$92.48M$570.00K
Net change in cash-$32.74M-$11.79M$66.70M$24.90M
Stock-based compensation$14.18M$8.32M$1.42M$4.70M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.04M$3.20M$3.26M$289.00K

Derived

Neurogene Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312018-12-31
Free cash flow-$78.36M-$71.41M-$51.74M-$31.63M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-8930.3%Unavailable-130.5%
FCF marginUnavailable-7720.1%Unavailable-126.5%
SBC / revenueUnavailable899.5%Unavailable18.8%
Current ratio16.56x20.84x8.72x16.68x
Revenue YoY growth-100.0%UnavailableUnavailableUnavailable
Net marginUnavailable-8123.7%Unavailable-126.3%
R&D / revenueUnavailable6585.6%UnavailableUnavailable
CapEx / revenueUnavailable87.4%Unavailable0.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NGNE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.